Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations. / Steffensen, Ane Y; Jønson, Lars; Ejlertsen, Bent; Gerdes, Anne-Marie; Nielsen, Finn C; Hansen, Thomas V O.
I: Familial Cancer, Bind 9, Nr. 3, 01.09.2010, s. 283-7.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations
AU - Steffensen, Ane Y
AU - Jønson, Lars
AU - Ejlertsen, Bent
AU - Gerdes, Anne-Marie
AU - Nielsen, Finn C
AU - Hansen, Thomas V O
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Mutations in the two breast cancer susceptibility genes BRCA1 and BRCA2 are associated with increased risk of breast and ovarian cancer. Patients with mutations in both genes are rarely reported and often involve Ashkenazi founder mutations. Here we report the first identification of a Danish breast and ovarian cancer family heterozygote for mutations in the BRCA1 and BRCA2 genes. The BRCA1 nucleotide 5215G > A/c.5096G > A mutation results in the missense mutation Arg1699Gln, while the BRCA2 nucleotide 859 + 4A > G/c.631 + 4A > G is novel. Exon trapping experiments and reverse transcriptase (RT)-PCR analysis revealed that the BRCA2 mutation results in skipping of exon 7, thereby introducing a frameshift and a premature stop codon. We therefore classify the mutation as disease causing. Since the BRCA1 Arg1699Gln mutation is also suggested to be disease-causing, we consider this family double heterozygote for BRCA1 and BRCA2 mutations.
AB - Mutations in the two breast cancer susceptibility genes BRCA1 and BRCA2 are associated with increased risk of breast and ovarian cancer. Patients with mutations in both genes are rarely reported and often involve Ashkenazi founder mutations. Here we report the first identification of a Danish breast and ovarian cancer family heterozygote for mutations in the BRCA1 and BRCA2 genes. The BRCA1 nucleotide 5215G > A/c.5096G > A mutation results in the missense mutation Arg1699Gln, while the BRCA2 nucleotide 859 + 4A > G/c.631 + 4A > G is novel. Exon trapping experiments and reverse transcriptase (RT)-PCR analysis revealed that the BRCA2 mutation results in skipping of exon 7, thereby introducing a frameshift and a premature stop codon. We therefore classify the mutation as disease causing. Since the BRCA1 Arg1699Gln mutation is also suggested to be disease-causing, we consider this family double heterozygote for BRCA1 and BRCA2 mutations.
U2 - http://dx.doi.org/10.1007/s10689-010-9345-6
DO - http://dx.doi.org/10.1007/s10689-010-9345-6
M3 - Journal article
VL - 9
SP - 283
EP - 287
JO - Familial Cancer
JF - Familial Cancer
SN - 1389-9600
IS - 3
ER -
ID: 34104632